296 related articles for article (PubMed ID: 9055014)
1. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
Chua SH; Goh CL; Ang CB
Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
[TBL] [Abstract][Full Text] [Related]
2. Topical therapy of alopecia areata with squaric acid dibutylester.
Case PC; Mitchell AJ; Swanson NA; Vanderveen EE; Ellis CN; Headington JT
J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
[TBL] [Abstract][Full Text] [Related]
3. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
Morita K; Nakamura M; Nagamachi M; Kishi T; Miyachi Y
J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
Orecchia G; Malagoli P; Santagostino L
Pediatr Dermatol; 1994 Mar; 11(1):65-8. PubMed ID: 8170854
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic approach with squaric acid dibutylester for steroid resistant-alopecia areata incognita: A pilot study of a single center.
Starace M; Vezzoni R; Alessandrini A; Bruni F; Carpanese MA; Misciali C; Sechi A; Piraccini BM
Dermatol Ther; 2021 Sep; 34(5):e15096. PubMed ID: 34390608
[TBL] [Abstract][Full Text] [Related]
7. Treatment of alopecia areata with squaric acid dibutylester.
Micali G; Cicero RL; Nasca MR; Sapuppo A
Int J Dermatol; 1996 Jan; 35(1):52-6. PubMed ID: 8838932
[TBL] [Abstract][Full Text] [Related]
8. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H
Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
[TBL] [Abstract][Full Text] [Related]
9. Squaric acid sensitization is not required for response in the treatment of alopecia areata.
Vedak P; Kroshinsky D
J Am Acad Dermatol; 2015 Sep; 73(3):471-6. PubMed ID: 26282797
[TBL] [Abstract][Full Text] [Related]
10. Topical immunotherapy with squaric acid dibutylester: unusual hair pigmentary changes in two cases of alopecia areata.
Mastrolonardo M; Diaferio A
J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):186. PubMed ID: 12046838
[No Abstract] [Full Text] [Related]
11. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis.
Tosti A; Guidetti MS; Bardazzi F; Misciali C
J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):199-201. PubMed ID: 8708020
[TBL] [Abstract][Full Text] [Related]
12. Alopecia areata: more on topical sensitizers.
Orecchia G; Marelli MA; Perfetti L; Rabbiosi G
Dermatologica; 1990; 180(2):57-9. PubMed ID: 2311796
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
Ajith C; Gupta S; Kanwar AJ
J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
[TBL] [Abstract][Full Text] [Related]
14. Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation.
Losol E; Şentürk N
Dermatol Ther; 2021 Jan; 34(1):e14726. PubMed ID: 33377267
[TBL] [Abstract][Full Text] [Related]
15. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
Kagami S; Kishi Y; Hino H
J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
[TBL] [Abstract][Full Text] [Related]
16. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
Lee S; Kim BJ; Lee YB; Lee WS
JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
[TBL] [Abstract][Full Text] [Related]
17. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
[TBL] [Abstract][Full Text] [Related]
18. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
[TBL] [Abstract][Full Text] [Related]
19. Angioedema After Squaric Acid Treatment in a 6-Year-Old Girl.
Chen CA; Carlberg V; Kroshinsky D
Pediatr Dermatol; 2017 Jan; 34(1):e44-e46. PubMed ID: 27699860
[TBL] [Abstract][Full Text] [Related]
20. Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after an additional follow-up period of 19 months.
van der Steen PH; Boezeman JB; Happle R
Dermatology; 1992; 184(3):198-201. PubMed ID: 1392112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
